What happens when the small business pipleline for lifesaving drugs goes dark?

Small businesses funded through the SBIR program have developed drugs generating $36 billion in annual sales; treating everything from Hodgkin's lymphoma to breast cancer. Now, nearly two months into the program's lapse, those cash-strapped innovators face mounting uncertainty as solicitations freeze and funding disappears. Jere Glover of the Small Business Technology Council joins us with an update. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info .